Toggle menu

ATTEST2

Start date:
July 2017
End date:
January 2021
Co-ordinated by:
The Stroke Research Team
Main trial site:
NHS Greater Glasgow & Clyde

ATTEST 2 aims to test tenecteplase in a large clinical trial to establish whether it is a better drug than alteplase for use in thrombolysis. This will involve a large number of hospitals in the UK, and possibly overseas. People who are considered suitable for thrombolysis will be allocated at random to receive either the current standard treatment with alteplase, or tenecteplase, and will be followed up for the first 90 days to measure the effects on recovery.
Even if there are no significant differences between between the two drugs, tenecteplase is less expensive and much easier to give to patients than alteplase, needing a single injection only. Alteplase has to be given as an injection followed by a longer injection over an hour. This advantage of tenecteplase alone would have worthwhile benefits to the patient.

Trial Design
Prospective Randomised Open, Blinded End-point (PROBE) – Phase III

Principal Investigator
Dr. Will Whitely, Stroke Medicine, University of Edinburgh & NHS Lothian

Chief Investigator

Dr William Whitely

Scottish Senior Clinical Fellow and Consultant Neurologist

Local PI

Dr Matt Reed

Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

Research Team

Rachel O'Brien

Lead Research Nurse

Allan MacRaild

Stroke Lead Research Nurse

Polly Black

Senior Research Nurse

Caroline Blackstock

AMU Senior Research Nurse

Sian Dalgleish

Senior Research Nurse

Alison Williams

Senior Research Nurse

Fiona McCurrach

Senior Research Nurse

Seona Burgess

Senior Stroke Research Nurse

More EMERGE Trials

The Emergency Medicine Annotated Bioresource Consortium (EM-ABC): A pilot and feasability programme

Read more

EMERGE Biobank

Developing a bioresource for all emergency presentations

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)

Read more

SABER

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)

TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.

Read more

TARGET-CTCA